CKD patients with fluid overload, confirmed by bioimpedance spectroscopy Acetazolamide, loop diuretics, chronic kidney disease, volume overload
Conditions
Interventions
Acetazolamide 250 mg per day, oral form, combined with same dose of baseline furosemide,Doubled-dose of furosemide per oral from baseline dose
Experimental Drug,Active Comparator Drug
Combination of acetazolamide and furosemide,Doubled-dose furosemide
Sponsors
Internal medicine, Phramongkutklao hospital
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. CKD stage III-V 2. Body composition monitoring overhydration > 1 L 3. Stable dose loop diuretics at least 2 weeks
Exclusion criteria
Exclusion criteria: 1. On acetazolamide within 12 weeks 2. Allergy to sulfa drugs 3. Organ transplant recipient 4. Pregnancy 5. Proteinuria > 3.5 g/d 6. Hospitalized within 12 weeks 7. Metabolic acidosis/alkalosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body weight 2 weeks Weighing scale calibrated for accuracy using weights authenticated by a government department of weights and measures | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of body fluid compartment from body composition monitoring 2 weeks Bioimpedence spectroscopy technique,Urinary sodium excretion 2 weeks Urinary sodium,Adverse event 2 weeks Rate of hypokalemia, hyponatremia, severe metabolic acidosis, AKI | — |
Countries
Thailand
Contacts
Public ContactJiranat Sriswasdi
Royal Thai Army Medical Department
Outcome results
None listed